Observational Study on Cancer Data Collection
This is an observational study, meaning you won't receive any new treatments or interventions. Researchers are collecting a large amount of information, including clinical data, imaging data, and 'omics data' (which looks at things like genes and proteins), from people with Diffuse Large B Cell Lymphoma and solid tumor cancers. The goal is to find specific genes or proteins that could be targets for new drugs or act as new biomarkers (indicators of disease) for different patient groups. This study aims to understand cancer better to help develop more personalized treatment strategies. You can join if you are 18 or older and provide consent.
- Study design
- This is an observational study with a planned enrollment of 7000 participants. It is not testing a specific drug or intervention.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your data will be collected from the date of cancer diagnosis until death, loss of follow-up, consent withdrawal, or the end of the study (December 2028), whichever comes first, for up to 16 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology
At a glance
Conditions
NCT06625203
Where you'd take part
This study runs at 5 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerlandstudy coordinator listed
Recruiting
Charité - Universitätsmedizin Berlin
Berlin, Germanystudy coordinator listed
Recruiting
Gustave Roussy
Paris, Francestudy coordinator listed
Recruiting
University of Pittsburgh
Pittsburgh, Pennsylvaniastudy coordinator listed
Recruiting
Universiy Hospital Erlangen & FAU Erlangen-Nürnberg
Erlangen, Germanystudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Dr. Vassili Soumelis · STUDY_CHAIR · Owkin
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- The primary endpoint will be genes or proteins that present features compatible with drug targeting and/or novel biomarkers, and that are specific to a given patient population within one or more cancer indications.From date of cancer diagnosis until date of death, date of lost of follow-up, date of consent withdrawal, or date of end of study (Dec 2028), whichever occurs first, assessed up to 16 years
Unsupervised data analysis and outcome measures will be used to achieve this, such as prognosis under treatment, response to specific therapies. The response to therapy will be assessed based on the data related to the treatment and its efficacy collected via an electronic Case Report Form. For each patient at baseline and throughout the MOSAIC follow up period, the following data will help to assess this: all the different cancer treatments (surgery,…) and their outcomes ; the concurrent treatment (drug name, …); the state of the cancer, i.e complete or partial response, or progression, measured at various time-points specific to each tumor type. Because the study will utilize tumor samples collected largely \<10 years ago, survival information may not be present for all patients by the end of the study, especially in slow evolving tumor types. For this reason, we will use tumor type-specific prognostic markers and scores as surrogates of prognosis whenever available and necessary.